Flemish Joint Effort for Biomarker PRofiling in Inflammatory Systemic Diseases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversity Hospital, Ghent
About this trial
A multi-centre, prospective study to study cytokine profiles and other potential disease-specific biomarkers in patients with presumed or confirmed diseases of systemic inflammation
The goal of this prospective, observational study is to describe the longitudinal evolution of blood cytokine profiles in patients with presumed or confirmed diseases of systemic inflammation
The main questions it aims to answer are:
* What are the differences and similarities in blood cytokines between different patients and groups presenting symptoms of systemic inflammatory conditions? * How is the cytokine profile of individual patients evolving over time and what is the effect of different therapeutics? * Is cytokine profiling a valuable tool to diagnose and follow-up on patients with systemic inflammatory conditions?
Participants will be asked to give an additional blood volume for research purposes when blood sampling is performed for routine clinical purposes. A subset of patients (those initiated on biologicals) will also be asked to complete questionnaires.
Researchers will compare the blood cytokines profiles between the different groups of systemic inflammatory conditions and with healthy individuals.
Eligibility criteria
Qualifiers
Child or adult
Written informed consent
Autoinflammatory diseases (AID), including among others: systemic onset juvenile idiopathic arthritis (sJIA), familial mediterranean fever (FMF), mevalonate kinase deficiency (Hyper IgD syndrome), TNF receptor-associated periodic syndrome (TRAPS), familial Cold Autoinflammatory Syndrome (CAPS), type 1 interferonopathies,…
Autoimmune diseases (AI), including among others: systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), rheumatoid arthritis (RA),…
Disqualifiers
Confirmed localized infection and/or good response to first-line antibiotic treatment
Confirmed malignancy
Trial design
Treatments tested in this trial
- cytokine and lipidomic profiling
Treatment groups
2,500 Participants
are divided into 1 treatment groupSponsors and collaborators
University Hospital, Ghent
Lead sponsor
University Hospital, Antwerp
Collaborator
Ziekenhuis Netwerk Antwerpen (ZNA)
Collaborator
Universitair Ziekenhuis Brussel
Collaborator
Jessa Hospital
Collaborator
Hasselt University
Collaborator
Source ClinicalTrials.gov